Novartis Ag (NVSEF) Prepaid Assets (2009 - 2026)
Novartis Ag's (NVSEF) quarterly Prepaid Assets came in at $100.0 million in Q1 2026, down 91.33% quarter-over-quarter from $1.2 billion in Q4 2025.
Novartis Ag (NVSEF) Prepaid Assets (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Prepaid Assets across 13 years of filings, most recently posting $100.0 million for Q1 2026.
- Prepaid Assets for Q1 2026 came in at $100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $100.0 million (changed N/A YoY), and the FY2025 annual result was $1.2 billion, up 17.06% from the prior year.
- Prepaid Assets came in at $100.0 million for Q1 2026 at Novartis Ag, down from $1.2 billion in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $3.5 billion in Q2 2025 to a low of $5.0 million in Q1 2022.
- The 5-year median for Prepaid Assets is $1.8 billion (2022), against an average of $1.7 billion.
- Across the five-year window, Prepaid Assets tumbled 99.81% in 2022 and soared 56460.0% in 2023, its largest moves.
- Novartis Ag's Prepaid Assets stood at $2.5 billion in 2022, then grew by 5.5% to $2.6 billion in 2023, then plunged by 62.22% to $985.0 million in 2024, then increased by 17.06% to $1.2 billion in 2025, then tumbled by 91.33% to $100.0 million in 2026.
- The last three Prepaid Assets figures came in at $100.0 million (Q1 2026), $1.2 billion (Q4 2025), and $3.5 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.00 Mn |
| Dec 31, 2025 | 1.15 Bn |
| Jun 30, 2025 | 3.46 Bn |
| Dec 31, 2024 | 985.00 Mn |
| Jun 30, 2024 | 3.03 Bn |
| Dec 31, 2023 | 2.61 Bn |
| Jun 30, 2023 | 2.83 Bn |
| Dec 31, 2022 | 2.47 Bn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 2.44 Bn |
| Jun 30, 2021 | 2.69 Bn |
| Dec 31, 2020 | 2.52 Bn |
| Jun 30, 2020 | 2.73 Bn |
| Dec 31, 2019 | 2.68 Bn |
| Jun 30, 2019 | 2.79 Bn |
| Mar 31, 2019 | 435.00 Mn |
| Dec 31, 2018 | 2.86 Bn |
| Sep 30, 2018 | 8.00 Mn |
| Jun 30, 2018 | 2.83 Bn |